NVAX Q1 2025 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$667M+610.3% YoY

Gross Profit

$653M97.9% margin

Operating Income

$516M77.3% margin

Net Income

$519M77.8% margin

EPS (Diluted)

$2.93

QoQ Revenue Growth

+654.9%

Cash Flow

Operating Cash Flow

-$186M

Free Cash Flow

-$187M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$1.4B

Stockholders' Equity

-$76M

Cash & Equivalents

$263M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$667M	$94M	+610.3%
Gross Profit	$653M	$45M	+1348.6%
Operating Income	$516M	-$139M	+471.6%
Net Income	$519M	-$148M	+451.5%

Revenue Segments

Nuvaxovid Sales

$608M91%

Royalties and Other

$45M7%

Supply Sales

$14M2%

Geographic Segments

CANADA

$576M86%

Rest of the World

$43M6%

UNITED STATES

$39M6%

Europe

$8M1%